Medication

|

11

FDA Says Weight Loss Drug Lorcaserin May Increase Risk of Cancer

The FDA has issued a safety alert for the weight management medicine Belviq, Belviq XR (lorcaserin) due to a possible increased risk of cancer with …

| | | |

Swiss Drugmaker Halts Distribution of Zantac Worldwide

Novartis AG’s Sandoz unit, the maker of ranitidine, or Zantac, a popular heartburn medication announced today it would halt global …

|

Vivimed Voluntarily Recalls Losartan Potassium Tablets due to Impurity

Vivimed Life Sciences is recalling 19 lots of Losartan Potassium Tablets USP 25 mg, 50 mg, and 100 mg due to the detection of an impurity that is …

|

Prostate Medicines Linked to Type 2 Diabetes Risk, Study Suggests

Researchers say patients should continue to take the drugs, which are commonly prescribed to older men, but warn they may need additional health …

FDA Issues Voluntary Recall of Blood Pressure Medication Due to Cancer Concerns

A voluntary recall of a blood pressure medication due to impurities, which may lead to a cancer risk, was recently issued by Sandoz Inc. The company …

| |

Xeris Pharma Announces FDA to Review NDA for Its Ready-to-Use Glucagon Rescue Pen

Xeris Pharmaceuticals, Inc. announced today that its new drug application (NDA) for its ready-to-use, room-temperature stable liquid glucagon rescue …

|

FDA Approves New Influenza Drug, Just in Time for Flu Season

Genentech announced yesterday that the U.S. Food and Drug Administration (FDA) has approved XOFLUZA™ for the treatment of the flu, in patients …

Down the Inhaled Insulin Path: The Road to Approval and Acceptance

Since the discovery of insulin over 85 years ago, scientists have been looking for ways to get it into the bodies of people without having to use …

|

Antibiotics Early in Childhood May Increase Risk for Type 1 Diabetes

Just one course of antibiotics taken early in childhood may increase the risk for type 1 diabetes, a new study from NYU Medical School finds. …

|

Type 2 Diabetes Medicines You Inject

1. Bydureon What is Bydureon? Bydureon is a member of the GLP-1 receptor agonist* family of medicines. Bydureon works in several places in the body, …

|